Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)
DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Castration-Resistant Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
- DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration-Resistant Prostate Cancer treatment.
- The leading Metastatic Castration-Resistant Prostate Cancer Companies working in the market include Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
- Promising Metastatic Castration-Resistant Prostate Cancer Therapies in the various stages of development include JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
- May 2024:- Janssen Research & Development LLC- A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer. The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of JNJ-78278343 and combination agent in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of JNJ-78278343 with the combination agent in Part 2 (dose expansion).
- May 2024:- Bristol-Myers Squibb- A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer. The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
- May 2024:- Fusion Pharmaceuticals Inc.- A Phase 2/3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of FPI-2265 (225Ac-PSMA-I&T) in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC), Previously Treated With 177Lu-PSMA Radioligand Therapy (RLT). The purpose of the dose optimization segment (Phase 2) is to determine the recommended FPI-2265 dose and regimen. Conclusions from Phase 2 will be based on safety, tolerability, and anti-tumor activity.
Request a sample and discover the recent advances in Metastatic Castration-Resistant Prostate Cancer treatment drugs @ Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook Report
Metastatic Castration-Resistant Prostate Cancer Overview
Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT).
Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years. CRPC was previously named “hormone-refractory prostate cancer” and “androgen-independent prostate cancer”. However, because castration treatments including ADT were ineffective, these cancers still showed reliance upon hormones for androgen receptor (AR) activation.
Metastatic Castration-Resistant Prostate Cancer Emerging Drugs Profile
- SRF617: Surface Oncology
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.
- Rucaparib: Clovis Oncology
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.
- HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
Find out more about Metastatic Castration-Resistant Prostate Cancer treatment drugs @ Drugs for Metastatic Castration-Resistant Prostate Cancer Treatment
Metastatic Castration-Resistant Prostate Cancer Therapeutics Assessment
There are approx. 75+ key Metastatic Castration-Resistant Prostate Cancer companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The Metastatic Castration-Resistant Prostate Cancer companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology.
DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report covers around 75+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Learn more about the emerging Metastatic Castration-Resistant Prostate Cancer pipeline therapies @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials
Metastatic Castration Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Oral
- Intravenous
- Subcutaneous
Metastatic Castration-Resistant Prostate Cancer Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Metastatic Castration-Resistant Prostate Cancer Companies
Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
Dive deep into rich insights for new drugs for Metastatic Castration-Resistant Prostate Cancer Treatment, visit @ Metastatic Castration-Resistant Prostate Cancer Drugs
Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
- Coverage- Global
- Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Metastatic Castration-Resistant Prostate Cancer Companies- Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
- Metastatic Castration-Resistant Prostate Cancer Therapies- JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
For further information on the Metastatic Castration-Resistant Prostate Cancer Pipeline Therapeutics, reach out @ Metastatic Castration-Resistant Prostate Cancer Treatment Drugs
Table of Content
- Introduction
- Executive Summary
- Metastatic Castration Resistant Prostate cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic Castration Resistant Prostate cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Rucaparib: Clovis Oncology
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Surface Oncology: SRF 617
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- REGN 4336: Regeneron Pharamceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- HP 518: Hinova Pharmaceuticals
- Drug profiles in the detailed report…..
- Inactive Products
- Metastatic Castration Resistant Prostate cancer Key Companies
- Metastatic Castration Resistant Prostate cancer Key Products
- Metastatic Castration Resistant Prostate cancer- Unmet Needs
- Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
- Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
- Metastatic Castration Resistant Prostate cancer Analyst Views
- Metastatic Castration Resistant Prostate cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
){kind=link}